Pfizer begins safety tests for new eczema drug in healthy volunteers
NCT ID NCT06686797
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 31 times
Summary
This early-stage study tests a new medicine called PF-08049820, being developed for moderate to severe eczema (atopic dermatitis). The study involves 71 healthy adults aged 18 to 65 to check the drug's safety, how the body processes it, and whether food affects its absorption. Participants receive single or multiple doses of the drug or a placebo, with close monitoring and follow-up for about a month.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer Clinical Research Unit - New Haven
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.